tradingkey.logo
tradingkey.logo
Search

Eton Pharmaceuticals Inc

ETON
Add to Watchlist
37.500USD
+0.870+2.38%
Close 07/02, 13:00ETQuotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM

More Details of Eton Pharmaceuticals Inc Company

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc Info

Ticker SymbolETON
Company nameEton Pharmaceuticals Inc
IPO dateNov 09, 2018
CEOBrynjelsen (Sean E)
Number of employees31
Security typeOrdinary Share
Fiscal year-endNov 09
Address21925 W Field Pkwy Ste 235
CityDEER PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60010-7278
Phone18477877361
Websitehttps://etonpharma.com/
Ticker SymbolETON
IPO dateNov 09, 2018
CEOBrynjelsen (Sean E)

Company Executives of Eton Pharmaceuticals Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

FAQs

Who are the top five shareholders of Eton Pharmaceuticals Inc?

The top five shareholders of Eton Pharmaceuticals Inc are: Mr. Sean E. Brynjelsen

How many institutions hold shares of Eton Pharmaceuticals Inc (ETON)?

As of 2026Q1, 235 institutions hold shares of Eton Pharmaceuticals Inc, with a combined market value of approximately 15.99M, accounting for 58.43% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -3678435.00.